Nexavar does not arrive at finally principal endpoint in Period 3 NExUS examination for the benefit of advanced NSCLC
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the fixed criticism of the Work in 3 NExUS (NSCLC check out Participation Utilizing Sorafenib) irritant evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cubicle lung cancer (NSCLC) showed that the consider did not devise its elementary endpoint of improving comprehensive survival in the first-line stage set. NExUS evaluated Nexavar versus placebo in mix with two chemotherapeutic agents, gemcitabine and cisplatin. A undeniable unoriginal endpoint of progression-free survival (PFS) was observed in the examination. The security and tolerability of the treatment triplet was as expected and did not playing any unknown or unexpected toxicities. Data from this investigation are expected to be presented at an upcoming systematic meet.
Nexavar is currently marketed worldwide representing the treatment of hepatocellular carcinoma (HCC), or liver cancer, and advanced renal apartment carcinoma (RCC), or kidney cancer.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
